Search

Your search keyword '"Dufies, Maeva"' showing total 240 results

Search Constraints

Start Over You searched for: Author "Dufies, Maeva" Remove constraint Author: "Dufies, Maeva"
240 results on '"Dufies, Maeva"'

Search Results

1. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

3. A Potent Solution for Tumor Growth and Angiogenesis Suppression via an ELR+CXCL-CXCR1/2 Pathway Inhibitor

5. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression

6. Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma

7. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma

8. A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma

9. Supplementary Figure Legends from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

10. Supplemental Figure S3 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

11. Data from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

12. Supplemental Figure 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

13. Data from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

14. Figure S3 from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

15. Supplemental Table S1 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

16. Supplemental Table 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

17. Supplementary Data from PGC1α Inhibits Polyamine Synthesis to Suppress Prostate Cancer Aggressiveness

18. Data from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

19. Supplementary Figures 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

20. Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

21. Supplementary Figure Legends 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

23. Targeting of the ELR+CXCL/CXCR1/2 Pathway Is a Relevant Strategy for the Treatment of Paediatric Medulloblastomas

24. New splice variants of VEGF as relevant targets for the treatment of renal cell carcinoma

25. In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study

26. Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy

28. UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFR signaling

29. Author response: UBTD1 regulates ceramide balance and endolysosomal positioning to coordinate EGFR signaling

30. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients

31. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

32. Cabozantinib, a Promising Therapeutic Strategy for Resistant Head and Neck Squamous Cell Carcinoma Patients

33. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy

34. Evidences of a Direct Relationship between Cellular Fuel Supply and Ciliogenesis Regulated by Hypoxic VDAC1-ΔC

40. Co‐culture of human fibroblasts, smooth muscle and endothelial cells promotes osteopontin induction in hypoxia

41. A novel mechanism of HIF2-dependent PLK1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma

43. A multi-layered systems approach for renal cell carcinoma

44. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

45. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients

46. Cancer‐associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti‐angiogenic therapy.

47. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments

48. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

49. Large expert-curated database for benchmarking document similarity detection in biomedical literature search

50. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma

Catalog

Books, media, physical & digital resources